一般演題口演 CKD English

[O-251] ZENITH-CKD：A Phase 2B Study of Zibotentan in Combination with Dapagliflozin and Dapagliflozin Alone in Patients with CKD

^○Arihiro Kiyosue¹, Hiddo Jan L. Heerspink², David C. Wheeler³, Tomoko Ishizu⁴, Min Lin⁵, Emma Wijkmark⁶, Glenn F. Carlson⁵, Anne-Kristina Mercier⁶, Magnus Astrand⁶, Peter J. Greasley⁶, Philip D. Ambery⁶ (1.Tokyo-EKI Center-building Clinic, Tokyo, Japan, 2.Universiteit Groningen, Groningen, Netherlands, 3.University College London, London, United Kingdom, 4.AstraZeneca, Tokyo, Japan, 5.AstraZeneca, Gaithersburg, USA, 6.AstraZeneca, Gothenburg, Sweden)